Sökning: onr:"swepub:oai:DiVA.org:liu-93386" >
Overall survival be...
-
Oakman, CHospital Prato, Italy
(författare)
Overall survival benefit for sequential doxorubicin-docetaxel compared with concurrent doxorubicin and docetaxel in node-positive breast cancer-8-year results of the Breast International Group 02-98 phase III trial
- Artikel/kapitelEngelska2013
Förlag, utgivningsår, omfång ...
-
Oxford University Press (OUP): Policy A1,2013
-
printrdacarrier
Nummerbeteckningar
-
LIBRIS-ID:oai:DiVA.org:liu-93386
-
https://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-93386URI
-
https://doi.org/10.1093/annonc/mds627DOI
Kompletterande språkuppgifter
-
Språk:engelska
-
Sammanfattning på:engelska
Ingår i deldatabas
Klassifikation
-
Ämneskategori:ref swepub-contenttype
-
Ämneskategori:art swepub-publicationtype
Anmärkningar
-
Funding Agencies|sanofi-aventis||Associazione Italiana Ricerca Cancro (AIRC), Milan, Italy||National Health and Medical Research Council|100925351164|Sanofi||Roche||Novartis||
-
Background: In women with node-positive breast cancer, the Breast International Group (BIG) 02-98 tested the incorporation of docetaxel (Taxotere) into doxorubicin (Adriamycin)-based chemotherapy, and compared sequential and concurrent docetaxel. At 5 years, there was a trend for improved disease-free survival (DFS) with docetaxel. We present results at 8-year median follow-up and exploratory analyses within biologically defined subtypes. less thanbrgreater than less thanbrgreater thanMethods: Patients were randomly assigned to one of four treatments: (i) sequential control: doxorubicin (A) (75 mg/m(2)) x 4 -andgt; classical cyclophosphamide, methotrexate, 5-fluorouracil (CMF); (ii) concurrent control: doxorubicin, cyclophosphamide (AC)(60/600 mg/m(2)) x 4 -andgt; CMF; (iii) sequential docetaxel: A (75 mg/m(2)) x3 -andgt; docetaxel (T) (100 mg/m(2)) x3. CMF and (iv) concurrent docetaxel: AT(50/75 mg/m(2)) x 4 -andgt; CMF. The primary comparison evaluated docetaxel efficacy regardless of the schedule. Exploratory analyses were undertaken within biologically defined subtypes. less thanbrgreater than less thanbrgreater thanResults: Two thousand eight hundred and eighty-seven patients were enrolled. After 93.4 months of median follow-up, there were 916 DFS events. For the primary comparison, there was no significant improvement in DFS from docetaxel [hazard ratio (HR) = 0.91, 95% confidence interval (CI) = 0.80-1.05, P = 0.187]. In secondary comparisons, sequential docetaxel significantly improved DFS compared with sequential control (HR = 0.81, 95% CI = 0.67-0.99, P = 0.036), and significantly improved DFS (HR = 0.84, 95% CI = 0.72-0.99, P = 0.035) and overall survival (OS) (HR = 0.79, 95% CI = 0.65-0.98, P = 0.028) compared with concurrent doxorubicin-docetaxel. Luminal-A disease had the best prognosis. HRs favored addition of sequential docetaxel in all subtypes, except luminal-A; but this observation was not statistically supported because of limited numbers. less thanbrgreater than less thanbrgreater thanConclusion: With further follow-up, the sequential docetaxel schedule resulted in significantly better OS than concurrent doxorubicin-docetaxel, and continued to show better DFS than sequential doxorubicin-based control.
Ämnesord och genrebeteckningar
-
adjuvant
-
breast cancer
-
chemotherapy
-
docetaxel
-
doxorubicin
-
sequential
-
MEDICINE
-
MEDICIN
Biuppslag (personer, institutioner, konferenser, titlar ...)
-
Francis, P A.Peter MacCallum Cancer Centre, Australia
(författare)
-
Crown, JIrish Clin Oncology Research Grp, Ireland
(författare)
-
Quinaux, EInt Institute Drug Dev, Belgium
(författare)
-
Buyse, MInt Institute Drug Dev, Belgium
(författare)
-
De Azambuja, EUniversity of Libre Brussels, Belgium
(författare)
-
Margeli Vila, MHospital Badalona Germans Trias and Pujol, Spain
(författare)
-
Andersson, MDanish Breast Cancer Cooperat Grp, Denmark
(författare)
-
Nordenskjöld, BoÖstergötlands Läns Landsting,Linköpings universitet,Onkologi,Hälsouniversitetet,Onkologiska kliniken US(Swepub:liu)bono64
(författare)
-
Jakesz, RVienna Medical Sch, Austria
(författare)
-
Thuerlimann, BKantonsspital, Switzerland
(författare)
-
Gutierrez, JClin Las Condes, Chile
(författare)
-
Harvey, VAuckland City Hospital, New Zealand
(författare)
-
Punzalan, LUniversity of Libre Brussels, Belgium
(författare)
-
DellOrto, PUniversity of Milan, Italy
(författare)
-
Larsimont, DUniversity of Libre Brussels, Belgium
(författare)
-
Steinberg, ISanofi Oncol, England
(författare)
-
Gelber, R D.IBCSG, MA USA
(författare)
-
Piccart-Gebhart, MUniversity of Libre Brussels, Belgium
(författare)
-
Viale, GUniversity of Milan, Italy
(författare)
-
Di Leo, AHospital Prato, Italy
(författare)
-
Hospital Prato, ItalyPeter MacCallum Cancer Centre, Australia
(creator_code:org_t)
Sammanhörande titlar
-
Ingår i:Annals of Oncology: Oxford University Press (OUP): Policy A124:5, s. 1203-12110923-75341569-8041
Internetlänk
Hitta via bibliotek
Till lärosätets databas
- Av författaren/redakt...
-
Oakman, C
-
Francis, P A.
-
Crown, J
-
Quinaux, E
-
Buyse, M
-
De Azambuja, E
-
visa fler...
-
Margeli Vila, M
-
Andersson, M
-
Nordenskjöld, Bo
-
Jakesz, R
-
Thuerlimann, B
-
Gutierrez, J
-
Harvey, V
-
Punzalan, L
-
DellOrto, P
-
Larsimont, D
-
Steinberg, I
-
Gelber, R D.
-
Piccart-Gebhart, ...
-
Viale, G
-
Di Leo, A
-
visa färre...
- Artiklar i publikationen
-
Annals of Oncolo ...
- Av lärosätet
-
Linköpings universitet